Roe-Pharma, a Canadian drug company, obtained a licence from Mega-mega-Pharma, a Swiss drug company, to sell Heptamyoextropalol in Canada. Reo-Pharma sells this patented medicine for $15 per pill
Generic Drugs Inc, another Canadian company, says that it can sell this drug for $2.50 per pill. Which of the following is true?
A) GDI can apply for a compulsory licence but it will not be granted because Reo-Pharma is using the patent.
B) GDI cannot apply for a compulsory licence pursuant to the Patent Law Amendment Act, 1992.
C) GDI will likely be granted a compulsory licence under the Patent Act because the price at which this drug is currently being sold is so high.
D) The Patented Medicine Price Review Board may reduce the price of Heptamyoextropalol if it feels it is excessive.
E) Both B and D
E
You might also like to view...
Product unit cost comprises only direct materials and direct labor costs
Indicate whether the statement is true or false
In the opening vignette, the Hillsborough accident occurred in ______.
a. Liverpool b. Nottingham c. Sheffield d. London
A ________ is an arrangement in which two or more business entities combine their resources to pursue a single project or transaction
A) limited partnership B) license agreement C) joint venture D) franchise
The ability of the customer to track their order from placement to delivery is
A) customer experience. B) order visibility. C) product availability. D) response time.